These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 33158162)

  • 1. Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures.
    Rizzo A; Tavolari S; Ricci AD; Frega G; Palloni A; Relli V; Salati M; Fenocchio E; Massa A; Aglietta M; Brandi G
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33158162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
    Montal R; Sia D; Montironi C; Leow WQ; Esteban-Fabró R; Pinyol R; Torres-Martin M; Bassaganyas L; Moeini A; Peix J; Cabellos L; Maeda M; Villacorta-Martin C; Tabrizian P; Rodriguez-Carunchio L; Castellano G; Sempoux C; Minguez B; Pawlik TM; Labgaa I; Roberts LR; Sole M; Fiel MI; Thung S; Fuster J; Roayaie S; Villanueva A; Schwartz M; Llovet JM
    J Hepatol; 2020 Aug; 73(2):315-327. PubMed ID: 32173382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.
    Rizzo A; Federico AD; Ricci AD; Frega G; Palloni A; Pagani R; Tavolari S; Marco MD; Brandi G
    Cancer Control; 2020; 27(1):1073274820983013. PubMed ID: 33356500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current options and future directions of systemic therapy for advanced biliary tract cancer.
    Prete MG; Cammarota A; D'Alessio A; Zanuso V; Rimassa L
    Explor Target Antitumor Ther; 2021; 2(5):416-433. PubMed ID: 36045701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives.
    Ten Haaft BH; Pedregal M; Prato J; Klümpen HJ; Moreno V; Lamarca A
    Eur J Cancer; 2024 Mar; 199():113564. PubMed ID: 38266541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic options for intrahepatic cholangiocarcinoma.
    Bupathi M; Ahn DH; Bekaii-Saab T
    Hepatobiliary Surg Nutr; 2017 Apr; 6(2):91-100. PubMed ID: 28503556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy in biliary tract cancers-current limitations and potentials in the future.
    Sahu S; Sun W
    J Gastrointest Oncol; 2017 Apr; 8(2):324-336. PubMed ID: 28480071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biliary tract cancers : Molecular characterization and identification of novel prognostic markers].
    Goeppert B
    Pathologe; 2017 Nov; 38(Suppl 2):192-197. PubMed ID: 29063951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current biologics for treatment of biliary tract cancers.
    Zhao DY; Lim KH
    J Gastrointest Oncol; 2017 Jun; 8(3):430-440. PubMed ID: 28736630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell of origin in biliary tract cancers and clinical implications.
    Moeini A; Haber PK; Sia D
    JHEP Rep; 2021 Apr; 3(2):100226. PubMed ID: 33665585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100354. PubMed ID: 33756174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M; Heumann T; Goff L; Agarwal R
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The epidemiological trends of biliary tract cancers in the United States of America.
    Jiang Y; Jiang L; Li F; Li Q; Yuan S; Huang S; Fu Y; Yan X; Chen J; Li H; Li S; Liu J
    BMC Gastroenterol; 2022 Dec; 22(1):546. PubMed ID: 36581813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapies for Perihilar Cholangiocarcinoma.
    Gray S; Lamarca A; Edeline J; Klümpen HJ; Hubner RA; McNamara MG; Valle JW
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):317-324. PubMed ID: 33054456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis.
    Clements O; Eliahoo J; Kim JU; Taylor-Robinson SD; Khan SA
    J Hepatol; 2020 Jan; 72(1):95-103. PubMed ID: 31536748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of metastasis and survival between extrahepatic and intrahepatic cholangiocarcinoma: A large population-based study.
    Liao P; Cao L; Chen H; Pang SZ
    Medicine (Baltimore); 2021 Apr; 100(16):e25635. PubMed ID: 33879742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100334. PubMed ID: 33592563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel insights into molecular and immune subtypes of biliary tract cancers.
    Bramel ER; Sia D
    Adv Cancer Res; 2022; 156():167-199. PubMed ID: 35961699
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.